- Offer price of USD 85.00 per share in cash represents a premium of approximately 41% over The Medicines Company’s 30-day volume weighted average price of USD 60.33; valuing the company at approximately USD 9.7 billion on a fully diluted basis
Slingshot members are tracking this corporate initiative:
Novartis(NVS) to acquire The Medicines Company(MDCO) for USD 9.7 bn, adding inclisiran, investigational cholesterol-lowering therapy
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Nov 24, 2019 Projected Implementation: Q4, 2019 Relevance Tracked Until: Q1, 2020
Don’t see a project related to the strategic initiative you care about?
Related Keywords Inclisiran, Cholesterol Lowering